9.91
-0.65
(-6.15%)
As of 2:32:03 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
449,749
449,749
457,433
463,292
472,308
Cost of Revenue
162,303
162,303
167,050
169,346
175,971
Gross Profit
287,446
287,446
290,383
293,946
296,337
Operating Expense
289,547
289,547
301,638
311,287
263,157
Operating Income
-2,101
-2,101
-11,255
-17,341
33,180
Net Non Operating Interest Income Expense
-11,837
-11,837
-20,234
-10,870
-405
Other Income Expense
-9,655
-9,655
-19,358
-26,289
-12,193
Pretax Income
-23,593
-23,593
-50,847
-54,500
20,582
Tax Provision
10,237
10,237
5,202
-7,596
4,185
Net Income Common Stockholders
-25,825
-25,825
-393,282
-63,881
-95,254
Diluted NI Available to Com Stockholders
-25,825
-25,825
-393,282
-63,881
-95,254
Basic EPS
-13.17
-0.94
-14.87
-2.45
-3.65
Diluted EPS
-13.17
-0.94
-14.87
-2.45
-3.65
Basic Average Shares
27,176.25
27,400
26,454
26,100
26,100
Diluted Average Shares
27,176.25
27,400
26,454
26,100
26,100
Total Operating Income as Reported
-20,664
-20,664
-30,939
-46,487
21,818
Total Expenses
451,850
451,850
468,688
480,633
439,128
Net Income from Continuing & Discontinued Operation
-25,825
-25,825
-393,282
-63,881
-95,254
Normalized Income
-19,165.23
-19,165.23
-40,498.64
-21,809.29
25,452.51
Interest Income
7,050
7,050
2,512
208
--
Interest Expense
18,887
18,887
22,746
11,078
405
Net Interest Income
-11,837
-11,837
-20,234
-10,870
-405
EBIT
-4,706
-4,706
-28,101
-43,422
20,987
EBITDA
29,606
29,606
93,585
79,367
150,706
Reconciled Cost of Revenue
152,044
152,044
71,876
73,539
74,548
Reconciled Depreciation
34,312
34,312
121,686
122,789
129,719
Net Income from Continuing Operation Net Minority Interest
-33,830
-33,830
-56,049
-46,904
16,397
Total Unusual Items Excluding Goodwill
-18,563
-18,563
-19,684
-29,146
-11,362
Total Unusual Items
-18,563
-18,563
-19,684
-29,146
-11,362
Normalized EBITDA
48,169
48,169
113,269
108,513
162,068
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-3,898.23
-3,898.23
-4,133.64
-4,051.29
-2,306.49
12/31/2021 - 2/16/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ZBH Zimmer Biomet Holdings, Inc.
112.72
+0.20%
LUNG Pulmonx Corporation
6.67
-2.20%
TMCI Treace Medical Concepts, Inc.
7.85
-5.65%
SRDX Surmodics, Inc.
30.17
-1.92%
VREX Varex Imaging Corporation
10.39
-9.10%
INGN Inogen, Inc.
6.92
-3.89%
ATEC Alphatec Holdings, Inc.
10.18
-2.63%
OFIX Orthofix Medical Inc.
15.59
-4.39%
ZIM.F Zimmer Biomet Holdings, Inc.
100.00
-3.61%
CVRX CVRx, Inc.
12.34
-4.93%